Pipeline

Major Depressive Disorder

More than 260 million people worldwide are affected by major depressive disorder (MDD), which is characterized by a persistently depressed mood or loss of interest in daily activities that can impact normal daily functioning, relationships, and overall quality of life. Treatments range from selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and antidepressants. Along with behavioral therapy, these medications benefit between 40–70% of people suffering from depression. One third of patients do not benefit adequately from these treatments.

Clinical Trials: Major Depressive Disorder

Neurocrine Biosciences plans to initiate a Phase 2 study of NBI-1065845 in patients as an adjunctive treatment for MDD in 2021.